Last reviewed · How we verify
bevacizumab intravitreal injection
Bevacizumab intravitreal injection, marketed by Asociación para Evitar la Ceguera en México, holds a position in the ophthalmic treatment landscape. The drug benefits from a key composition patent expiring in 2028, providing a period of market exclusivity. The primary risk is the lack of disclosed revenue data, which may affect investment and market valuation.
At a glance
| Generic name | bevacizumab intravitreal injection |
|---|---|
| Also known as | Avastin |
| Sponsor | Asociación para Evitar la Ceguera en México |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: A Randomized Trial of Pain, Procedure Time, Patient Satisfaction, and Safety (NA)
- Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema (PHASE3)
- Safety and Immunogenicity of PRO-169 in Patients With Diabetic Macular Edema (PHASE1)
- Bevacizumab Treatment For Type 1 ROP (PHASE2)
- Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema (NA)
- Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease (PHASE3)
- The Sahlgrenska Anti-VEGF Study (PHASE2)
- Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: